The ocular pharmacokinetics of topical diclofenac is affected by ocular inflammation

Ophthalmic Research

Volumn 31, Issue 4, 1999, Pages 309-316

  Palmero, M ^b   Bellot, J L ^b   Alcoriza, N ^b   Garcia Cabanes C ^b   Orts, Alfredo ^a  

^a UNIVERSITY OF ALICANTE   (Spain)

^b NONE

Author keywords

Clove oil induced keratitis; Diclofenac; Endotoxin induced uveitis; Pharmacokinetics

Indexed keywords

CLOVE OIL; DICLOFENAC; ENDOTOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS HUMOR; ARTICLE; CILIARY BODY; CONTROLLED STUDY; CORNEA; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; EYE INFLAMMATION; IRIS; KERATITIS; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; TOPICAL DRUG ADMINISTRATION; UVEITIS;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DICLOFENAC; EYE; KERATITIS; MALE; RABBITS; UVEITIS;

EID: 0032991006     PISSN: 00303747     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055552     Document Type: Article

References (14)

1. Agata M, Abe T, Kon M, Tanaka M, Kimura M, Nakajima A: Effect of topical diclofenac sodium, a non-steroidal anti-inflammatory drug, on various ocular inflammatory models in animals. Acta Soc Ophthalmol. Jpn 1983;87:19-28.
2. Van Husen H: Locale Behandlung mit Diclofenac-Na-Augentropfen bei Erkrankungen der vorderen Augenabschnitte. Klin Monatsbl Augenheilkd 1986;1886:615-619.
3. Goa KL, Chrisp P: Ocular diclofenac: A review of its pharmacology and clinical use in cataract surgery and potential in other antiinflammatory conditions. Drugs Actions 1992;2:473-486.
4. Kraff MC, Sanders DR, McGuigan L, Raanan MG: Inhibition of blood-aqueous barrier breakdown with diclofenac: A fluorophotometric study. Arch Ophthalmol 1990;108: 380-383.
5. Van Haeringen NJ, Glosius E, Oosterhuis JA, von Delft JL: Drug prevention of blood-aqueous barrier disruption. Ophthalmic Res 1983; 15:180-184.
6. Ronen S, Rozenman Y, Zylbermann R, Berson D: Treatment of ocular inflammation with diclofenac sodium: Double-blind trial following cataract surgery. Arch Ophthalmol 1985;17:577-581.
7. Bonomi L, Perfetti S, Belluci R, Massa F, de Franco I: Prevention of surgically induced miosis by diclofenac eye drops. Ann Ophthalmol 1987;19:142-145.
8. Riegel M, Ellis PP: High performance liquid chromatographic assay for anti-inflammatory agents diclofenac and flurbiprofen in ocular fluids. J Chromatogr B Biomed Appl 1994;18:140-145.
9. Ellis PP, Pfoff DS, Bloedow DC, Riegel H: Intraocular diclofenac and flurbiprofen concentrations in human aqueous humor following topical application. J Ocul Pharmacol 1994;10:677-682.
10. Vickers FF, John VA, Powell ML, Wysowskij H, Luders R, Brunner L, Ahmed M: Corneal penetration of 0.1 % diclofenac sodium ophthalmic solutions in patients undergoing cataract surgery. Annu Meet Am Coll Clin Pharmacol, Las Vegas, NV, November 4-8, 1990. J Clin Pharmacol 1990;30:835.
11. Borga O, Borga B: Serum protein binding of nonsteroidal antiinflammatory drugs: A comparative study. J Pharmacokinetic Biopharm 1997; 25:63-77.
12. Lin JH, Cocchetto DM, Duggan DE: Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs. Clin Pharmacokinetic 1987;12:402-432.
13. Hessemer V, Schmitt K, Jacobi A: Anti-inflammatory effects and aqueous humor concentration of various nonsteroidal anti-inflammatory drugs in extracapsular cataract surgery. Klin Monatsbl Augenheilkd 1996;208:161-166.
14. Ellis PP, Pfoff DS, Bloedow DC, Riegel M: Intraocular diclofenac and flurbiprofen concentrations in human aqueous humor following topical application. J Ocul Pharmacol 1994;10:677-682.